BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29921503)

  • 1. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
    Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
    J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
    Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
    BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
    Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
    Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
    Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
    J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers.
    Hoppe JE; Hinds DM; Colborg A; Wagner BD; Morgan WJ; Rosenfeld M; Zemanick ET; Sanders DB
    Pediatr Pulmonol; 2020 Dec; 55(12):3400-3406. PubMed ID: 32970375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.
    Waters VJ; Stanojevic S; Sonneveld N; Klingel M; Grasemann H; Yau YC; Tullis E; Wilcox P; Freitag A; Chilvers M; Ratjen FA
    J Cyst Fibros; 2015 Nov; 14(6):755-62. PubMed ID: 25690407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correspondence between symptoms and preference-based health status measures in the STOP study.
    Gold LS; Patrick DL; Hansen RN; Beckett V; Goss CH; Kessler L
    J Cyst Fibros; 2019 Mar; 18(2):251-264. PubMed ID: 30170756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
    Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
    PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Association between
    O'Dea AL; Feng R; Glaser LJ; Kubrak C; Rubenstein RC; Dorgan DJ; Hadjiliadis D; Kawut SM; Hong G
    Ann Am Thorac Soc; 2023 Jul; 20(7):984-992. PubMed ID: 36800434
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis.
    Schechter MS; Schmidt HJ; Williams R; Norton R; Taylor D; Molzhon A
    J Cyst Fibros; 2018 Nov; 17(6):769-778. PubMed ID: 30017327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
    Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
    BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
    Waters V; Stanojevic S; Klingel M; Chiang J; Sonneveld N; Kukkar R; Tullis E; Ratjen F
    J Cyst Fibros; 2015 Nov; 14(6):770-6. PubMed ID: 26265220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
    Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
    J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes.
    Cheney J; Vidmar S; Gailer N; Wainwright C; Douglas TA;
    J Cyst Fibros; 2020 May; 19(3):483-491. PubMed ID: 32165156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
    Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
    Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.